How will bispecific antibody therapies affect my quality of life? 

Each patient can have a different experience with bispecific antibody therapy and how it affects their quality of life. Studies are still emerging on the long-term quality of life effects of these treatments.

Some early findings are detailed below:  

• Patients on teclistamab have improved their quality of life in pain management with no overall change in physical function and fatigue. 
• Treatment with GPRC5D-targeting bispecifics such as talquetamab can significantly impact the quality of life due to early-onset side effects like loss of taste or taste changes, dry skin and dry mouth. However, patients also reported an improvement in pain, fatigue, and physical functioning. 
• Elranatamab patients are reported to maintain or improve their quality of life in areas such as pain, disease symptoms, side effects of treatment, body image, and future perspectives of treatment. 
• Patients taking linvoseltamab reported an improved quality of life. 

As more patients qualify for bispecific antibody therapy and more time passes, real-world data will provide concrete evidence of the impact of bispecific antibody therapies on quality of life.